Alphyn Completes Enrollment in Phase 2 Trial of Topical Therapy for Molluscum Contagiosum
Alphyn Completes Enrollment in Phase 2 Trial of Topical Therapy for Molluscum Contagiosum NEWS PROVIDED BY Alphyn Biologics Mar 24, 2026, 07:30 ET Company’s patented multi-target therapeutics® platform establishes a new class of patient-friendly treatments ANNAPOLIS, Md., March 24, 2026 /PRNewswire/ — Alphyn Biologics, Inc., a clinical-stage dermatology company developing the first Multi-Target Therapeutics® drug…